TRUDI: TDXD+Durva in HER2+/Low IBC

Clinical trial NCT05795101 · RECRUITING

Trial details

NCT number: NCT05795101
Sponsor: Filipa Lynce, MD
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Invasive Breast Cancer Inflammatory Breast Cancer Stage III HER2-positive Breast Cancer HER2 Low Breast Adenocarcinoma Breast Cancer

Start date: 2023-05-04
Primary completion: 2027-12-01
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.